



© FIND / Jacques Debayle

## Tomorrow's TB diagnostics today!



Single-tube high-multiplex PCR and subsequent fluorescence-based detection of *M. tuberculosis* complex and its resistance against rifampicin and isoniazid from sputum specimens and cultivated samples.

### Your benefits of using FluoroType<sup>®</sup> MTBDR

- **Novel technology:** The innovative FluoroType<sup>®</sup> technology is based on Asymmetric excess PCR and detection via Lights-On and Lights-Off probes. It thus enables reliable MDR-TB diagnostics within 3 hours only.
- **True MDR-TB testing:** Resistances to both first-line drugs, rifampicin and isoniazid, are reliably detected, as well as mono-resistances.
- **Flexible and intelligent software:** The user-friendly and machine learning, specific Fluoro-Software<sup>®</sup> does the evaluation and result interpretation. Common resistance-mediating mutations are specified within the result report. In addition, rare or so far unknown mutations in the target genes are also shown.
- **Fully automated solution possible:** Amplification and detection run fully automated in a closed system, the FluoroCycler<sup>®</sup> 96. An Internal control documents the correct test procedure and valid results. Nucleic acid extraction can be automated by using the GenoXtract<sup>®</sup> 96 device.

## Facts

Multidrug-resistant tuberculosis (MDR-TB) is an alarming and ongoing global issue which requires fast intervention in order to prevent further spread of the disease. More and more frequently, mono-resistant strains are found. Thus, utilising a test system that provides rapid and reliable results for the two most important first-line drugs, rifampicin and isoniazid, provides clinicians with greater information. In consequence, it allows them to make an informed decision on how to treat their patients with the most appropriate therapy. Our automated diagnostics offer convenience and standardization to laboratories allowing them to report high quality and reproducible results to their clinicians.

## FluoroType® MTBDR – Tomorrow's TB diagnostics today!



**FluoroType® MTBDR** is based on the innovative Asymmetric excess PCR technique with a subsequent fluorescence-based Lights-On and Lights-Off probe detection. Within one reaction the test allows for the detection of *M. tuberculosis* complex and mutations within the *rpoB*, *inhA* and *katG* genes. By using the **FluoroType®** technology also rare or so far unknown mutations in the target genes can be reliably detected. Besides, it is possible to enter information on novel mutations into the machine learning software in order to ensure their specification in the future.

DNA extraction can be performed manually or fully automated with the **GenoExtract® 96**. Using this instrument a completely automated processing is possible:

After DNA isolation and PCR set-up, the plate can be directly placed into the **FluoroCycler® 96** for amplification and detection. The results are evaluated and displayed in the **FluoroCycler® 96 Report**. Fully automated, fast and reliable results at one glance are therefore guaranteed.

Thus, **FluoroType® MTBDR** is a valuable tool in the fight against MDR-TB!

**For further information please contact Hain Lifescience.**

## Hain Lifescience GmbH

Hardwiesenstrasse 1 | 72147 Nehren | Germany

Tel.: +49 (0) 74 73- 94 51- 0 | Fax: +49 (0) 74 73- 94 51- 31

E-Mail: [info@hain-lifescience.de](mailto:info@hain-lifescience.de) | [www.hain-lifescience.de](http://www.hain-lifescience.de)

